OptiNose, Inc.

OPTN

US68404V1008

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.8604 ^USD	-4.93%		-3.78%	-33.30%

Apr. 25	Transcript : OptiNose, Inc. - Special Call
Apr. 25	OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	CI

OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024

March 07, 2024 at 07:00 am EST

OptiNose, Inc. provided earnings guidance for the first quarter of 2024. For the quarter, the Company expects XHANCE net revenues for the first quarter 2024 will be approximately $13.0 million.

Latest news about OptiNose, Inc.

Transcript : OptiNose, Inc. - Special Call	Apr. 25
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	Apr. 25	CI
Optinose, Inc. Announces Preliminary XHANCE Net Product Revenue Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating	Mar. 18	MT
Sector Update: Health Care Stocks Steady Premarket Monday	Mar. 18	MT
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis	Mar. 15	MT
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis	Mar. 15	DJ
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	Mar. 15	CI
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	Mar. 14	CI
HC Wainwright Initiates OptiNose With Buy Rating, $5 Price Target	Mar. 11	MT
Transcript : OptiNose, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Earnings Flash (OPTN) OPTINOSE Posts Q4 Revenue $19.9M	Mar. 07	MT
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024	Mar. 07	CI
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology	Jan. 18	CI
OptiNose, Inc.(NasdaqGS:OPTN) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Optinose Shares Slide Premarket as FDA Extends Xhance Review	Dec. 06	DJ
OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis	Dec. 06	MT
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE	Dec. 06	CI
Transcript : OptiNose, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (OPTN) OPTINOSE Posts Q3 Revenue $19.8M	Nov. 09	MT
OptiNose, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
OptiNose, Inc. Revises Revenue Guidance for the Full Year of 2023	Nov. 09	CI

OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for OptiNose, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8604 USD

Average target price

3.75 USD

Spread / Average Target

+335.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OPTINOSE, INC.	-33.30%	97.26M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

OptiNose, Inc.

Equities

OPTN

US68404V1008

Pharmaceuticals

OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024

Latest news about OptiNose, Inc.

Chart OptiNose, Inc.

Company Profile

Income Statement Evolution

Ratings for OptiNose, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals